25.46
price down icon0.16%   -0.04
after-market After Hours: 25.46
loading
Galapagos Nv Adr stock is traded at $25.46, with a volume of 81,476. It is down -0.16% in the last 24 hours and down -3.30% over the past month. Galapagos NV is a fully integrated biotechnology company focused on discovering, developing, and commercializing medicines. The company is committed to improving patients' lives world-wide by targeting diseases with high unmet needs. Its R&D capabilities cover multiple drug modalities, including small molecules and cell therapies. Its portfolio comprises discovery through to commercialized programs in immunology, oncology, and other indications. Its first medicine for rheumatoid arthritis and ulcerative colitis is available in Europe and Japan. It derives maximum revenue from United States of America.
See More
Previous Close:
$25.50
Open:
$25.56
24h Volume:
81,476
Relative Volume:
0.33
Market Cap:
$1.68B
Revenue:
$282.04M
Net Income/Loss:
$221.88M
P/E Ratio:
7.5643
EPS:
3.3658
Net Cash Flow:
$-449.57M
1W Performance:
-1.39%
1M Performance:
-3.30%
6M Performance:
-13.05%
1Y Performance:
-20.93%
1-Day Range:
Value
$25.26
$25.56
1-Week Range:
Value
$25.07
$26.39
52-Week Range:
Value
$22.36
$32.57

Galapagos Nv Adr Stock (GLPG) Company Profile

Name
Name
Galapagos Nv Adr
Name
Phone
-
Name
Address
-
Name
Employee
646
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
GLPG's Discussions on Twitter

Compare GLPG with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
GLPG
Galapagos Nv Adr
25.46 1.68B 282.04M 221.88M -449.57M 3.3658
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.69 131.41B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
637.36 72.26B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
589.15 35.93B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
268.46 34.75B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
267.39 28.24B 3.81B -644.79M -669.77M -6.24

Galapagos Nv Adr Stock (GLPG) Upgrades & Downgrades

Date Action Analyst Rating Change
Feb-14-25 Downgrade Morgan Stanley Equal-Weight → Underweight
Nov-20-24 Downgrade Kepler Hold → Reduce
Sep-09-24 Initiated Leerink Partners Market Perform
Aug-02-24 Downgrade Raymond James Outperform → Mkt Perform
Mar-28-24 Downgrade BofA Securities Neutral → Underperform
Mar-07-24 Resumed Morgan Stanley Equal-Weight
Aug-24-23 Downgrade Citigroup Buy → Neutral
May-05-23 Upgrade Raymond James Mkt Perform → Outperform
Jan-23-23 Upgrade Jefferies Underperform → Hold
Nov-07-22 Downgrade Raymond James Outperform → Mkt Perform
Sep-09-22 Downgrade Morgan Stanley Overweight → Equal-Weight
Jan-27-22 Upgrade Citigroup Neutral → Buy
Aug-19-21 Downgrade Barclays Overweight → Equal Weight
Aug-06-21 Downgrade Deutsche Bank Buy → Hold
Apr-20-21 Initiated Deutsche Bank Buy
Apr-14-21 Upgrade Barclays Equal Weight → Overweight
Feb-23-21 Upgrade BofA Securities Underperform → Neutral
Feb-19-21 Upgrade Raymond James Mkt Perform → Outperform
Feb-11-21 Downgrade Citigroup Buy → Neutral
Jan-19-21 Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-19-20 Initiated Maxim Group Buy
Oct-21-20 Downgrade Goldman Neutral → Sell
Aug-25-20 Downgrade Jefferies Buy → Hold
Aug-24-20 Downgrade H.C. Wainwright Buy → Neutral
Aug-19-20 Downgrade Barclays Overweight → Equal Weight
Aug-19-20 Upgrade Citigroup Neutral → Buy
Jul-10-20 Downgrade Stifel Buy → Hold
Mar-30-20 Upgrade Jefferies Hold → Buy
Mar-18-20 Upgrade RBC Capital Mkts Underperform → Sector Perform
Feb-25-20 Downgrade Cantor Fitzgerald Overweight → Neutral
Feb-24-20 Downgrade BofA/Merrill Neutral → Underperform
Feb-20-20 Downgrade RBC Capital Mkts Sector Perform → Underperform
Jan-06-20 Downgrade JP Morgan Overweight → Neutral
Dec-18-19 Downgrade Citigroup Buy → Neutral
Dec-17-19 Downgrade Morgan Stanley Overweight → Equal-Weight
Dec-13-19 Downgrade Credit Suisse Outperform → Neutral
Dec-02-19 Initiated BofA/Merrill Neutral
Sep-09-19 Resumed Morgan Stanley Overweight
Jul-31-19 Upgrade UBS Neutral → Buy
Jul-29-19 Downgrade Jefferies Buy → Hold
View All

Galapagos Nv Adr Stock (GLPG) Latest News

pulisher
Jan 21, 2025

Galapagos To Spin Off Innovative Medicines Business - Forbes

Jan 21, 2025
pulisher
Jan 09, 2025

Belgium stocks higher at close of trade; BEL 20 up 0.06% - Investing.com

Jan 09, 2025
pulisher
Jan 08, 2025

Galapagos Unveils 2025 Split To Accelerate Innovation, Sharpen Strategic Focus - Benzinga

Jan 08, 2025
pulisher
Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns - Investing.com

Nov 20, 2024
pulisher
Nov 20, 2024

Galapagos stock downgraded to Reduce on strategic concerns By Investing.com - Investing.com South Africa

Nov 20, 2024
pulisher
Nov 14, 2024

Belgium shares higher at close of trade; BEL 20 up 0.58% - MSN

Nov 14, 2024
pulisher
Nov 04, 2024

Deutsche Bank maintains Hold on Galapagos, reducing target with key updates months away - Investing.com

Nov 04, 2024
pulisher
Nov 01, 2024

Earnings call: Galapagos reports solid Q3 progress, eyes IND studies By Investing.com - Investing.com South Africa

Nov 01, 2024
pulisher
Nov 01, 2024

Earnings call: Galapagos reports solid Q3 progress, eyes IND studies - Investing.com

Nov 01, 2024
pulisher
Nov 01, 2024

Galapagos stock outlook cautious with clinical readouts on the horizon, says Morgan Stanley - Investing.com

Nov 01, 2024
pulisher
Oct 30, 2024

Galapagos ADR earnings missed by $0.05, revenue topped estimates - Investing.com UK

Oct 30, 2024
pulisher
Aug 26, 2024

Why This Rival To Gilead, Novartis Just Jumped 10% — And Why There Are Caveats - Investor's Business Daily

Aug 26, 2024
pulisher
Aug 23, 2024

Galapagos (GLPG) Up on FDA Nod to Begin Phase I/II Lymphoma Study - Yahoo Finance

Aug 23, 2024
pulisher
Apr 17, 2024

Citi lowers Galapagos NV shares target amid restructuring and pipeline investments By Investing.com - Investing.com

Apr 17, 2024
pulisher
Mar 07, 2024

Morgan Stanley sets Galapagos stock at equalweight, $38 price target - Investing.com

Mar 07, 2024
pulisher
Jan 27, 2022

Galapagos Surges On New CEO and Upgrade News - Investing.com

Jan 27, 2022
pulisher
Aug 30, 2021

Galapagos NV announces retirement of CEO - Seeking Alpha

Aug 30, 2021
pulisher
Sep 28, 2020

Galapagos Gets First Commercial Drug With Jyseleca Approval - Yahoo Finance

Sep 28, 2020
pulisher
Aug 19, 2020

The Daily Biotech Pulse: Gilead's Filgotinib Stumbles With FDA, J&J Laps Up Momenta In $6.5B Deal, 2 IPOs - Benzinga

Aug 19, 2020
pulisher
Feb 11, 2020

The Daily Biotech Pulse: LogicBio Slapped With Clinical Hold, Agile Inks Debt Deal Ahead of Twirla Approval, Gilead Builds Stake In Sierra Oncology - Yahoo Finance

Feb 11, 2020
pulisher
Jan 17, 2020

The Daily Biotech Pulse: Novo Nordisk's Ozempic Receives Label Expansion For Cardiovascular Events, Adcom Disappointment Inflicts Pain On Durect Shares - Yahoo Finance

Jan 17, 2020
pulisher
Apr 17, 2019

Galapagos NV (GLPG) Stock Price, Trades & News - GuruFocus.com

Apr 17, 2019
pulisher
Jul 27, 2018

AIM tech shares that broke America - Interactive Investor

Jul 27, 2018
pulisher
Jul 07, 2017

Galapagos Is More Attractive–But Don’t Buy It Just Yet - Barron's

Jul 07, 2017
pulisher
Dec 30, 2015

The 5 Best-Performing Non-S&P Stocks of 2015 - Forbes

Dec 30, 2015
pulisher
Jul 31, 2015

GalapagosAll Time High - Seeking Alpha

Jul 31, 2015

Galapagos Nv Adr Stock (GLPG) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$77.99
price up icon 0.39%
$306.97
price down icon 0.34%
$31.37
price down icon 0.88%
$20.32
price down icon 1.36%
$94.95
price down icon 0.47%
biotechnology ONC
$267.39
price up icon 1.82%
Cap:     |  Volume (24h):